FDA Approves PROLENSA from Bausch + Lomb

The FDA has granted Bausch + Lomb approval for PROLENSA, its anti-inflammatory prescription eye drop for patients that have undergone cataract surgery.

Advertisement

The bromfenac ophthalmic solution, which will be offered in 1.6ml and 3ml bottles, is designed to reduce ocular inflammation and pain.

More Articles on Ophthalmology:
Arizona Aiello Eye Institute Expands Services to Foothills Location
LENSAR Laser System Earns FDA 510(k) Clearance
Devers Eye Institute Offers Corneal Crosslinking

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.